These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26146489)

  • 1. Unlocking truths of γ-secretase in Alzheimer's disease: what is the translational potential?
    Wolfe MS
    Future Neurol; 2014; 9(4):419-429. PubMed ID: 26146489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Curr Top Med Chem; 2002 Apr; 2(4):371-83. PubMed ID: 11966461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γ-Secretase and its modulators: Twenty years and beyond.
    Xia W
    Neurosci Lett; 2019 May; 701():162-169. PubMed ID: 30763650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amyloid-beta forming tripeptide cleavage mechanism of γ-secretase.
    Bolduc DM; Montagna DR; Seghers MC; Wolfe MS; Selkoe DJ
    Elife; 2016 Aug; 5():. PubMed ID: 27580372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Processive proteolysis by γ-secretase and the mechanism of Alzheimer's disease.
    Wolfe MS
    Biol Chem; 2012 Sep; 393(9):899-905. PubMed ID: 22944690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
    Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
    Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
    Yan R; Bienkowski MJ; Shuck ME; Miao H; Tory MC; Pauley AM; Brashier JR; Stratman NC; Mathews WR; Buhl AE; Carter DB; Tomasselli AG; Parodi LA; Heinrikson RL; Gurney ME
    Nature; 1999 Dec; 402(6761):533-7. PubMed ID: 10591213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. gamma-Secretase modulators.
    Wolfe MS
    Curr Alzheimer Res; 2007 Dec; 4(5):571-3. PubMed ID: 18220525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.
    Raven F; Ward JF; Zoltowska KM; Wan Y; Bylykbashi E; Miller SJ; Shen X; Choi SH; Rynearson KD; Berezovska O; Wagner SL; Tanzi RE; Zhang C
    EBioMedicine; 2017 Oct; 24():93-101. PubMed ID: 28919280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
    Beher D; Graham SL
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeting the structure and function relationships of the gamma-secretase for the development of Alzheimer's disease].
    Tomita T
    Rinsho Shinkeigaku; 2008 Nov; 48(11):907-9. PubMed ID: 19198114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment.
    Wiley JC; Hudson M; Kanning KC; Schecterson LC; Bothwell M
    J Neurochem; 2005 Sep; 94(5):1189-201. PubMed ID: 15992373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease.
    Wolfe MS
    Int Immunopharmacol; 2002 Dec; 2(13-14):1919-29. PubMed ID: 12489805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-secretase (BACE) as a drug target for Alzheimer's disease.
    Vassar R
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1589-602. PubMed ID: 12453676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.